VEGFA and glioblastoma: High vascularization is a biological characteristic of GBM and the anti-angiogenic agent bevacizumab (BEV, a humanized monoclonal antibody targeting vascular endothelial growth factor) can lead to clinical improvement of patients with GBM; it is currently the only approved molecular targeted drug for the treatment of GBMs.